News

Press Releases

Press Releases

Press Releases

September 4, 2019
BRIDGEWATER, N.J. , Sept. 4, 2019 /PRNewswire/ --   Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced results of the Company's Extraordinary General Meeting. At the Extraordinary General Meeting of the Company
August 28, 2019
BRIDGEWATER, N.J. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Andrew Einhorn , Chief Financial Officer, will present at the 2019 Wells Fargo Healthcare Conference as
August 8, 2019
Second quarter 2019 total revenue of $57.5 million On track to submit NDA for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) for acquired blepharoptosis, or droopy eyelid, by end of Q3 2019 BRIDGEWATER, N.J. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc
Displaying 1 - 10 of 13